The Pharma Data
DECEMBER 4, 2020
And I think we’ll see a significant reduction” in the virus, Biden told CNN. The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities.
The Pharma Data
DECEMBER 3, 2020
Though coronavirus cases have exploded recently, with new infections topping 1 million a week, a far smaller proportion of people who get the virus now are dying from it. Around the world, researchers are testing 57 vaccines in clinical trials, and nearly 100 others are being tested in animals or cell, the Times reported.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
APRIL 14, 2021
Adverse events reported in at least 1% of BLAZE-1 clinical trial participants on bamlanivimab 700 mg alone or placebo were nausea (3% vs 4%), diarrhea (1% vs 5%), dizziness (3% vs 2%), headache (3% vs 2%), pruritus (2% vs 1%) and vomiting (1% vs 3%). Bamlanivimab alone. Source link:[link].
The Pharma Data
APRIL 16, 2021
1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. However, sites of care should not dispose of bamlanivimab supply; instead, they should order etesevimab to pair with it. All sites in the U.S. In the U.S.,
The Pharma Data
DECEMBER 2, 2020
The recommendation from the Advisory Committee on Immunization Practice (ACIP), if heeded, will steer the initial short supply of vaccines to about 21 million health care personnel and 3 million Americans working or living in long-term care facilities. The global race to develop a vaccine has been stunningly fast.
The Pharma Data
DECEMBER 19, 2020
Today’s ACIP recommendation follows the December 1, 2020 ACIP recommendation for a Phase 1a rollout in which the first priority for COVID-19 vaccines is given to healthcare personnel treating patients and residents in long-term care facilities. Department of Health and Human Services (HHS) for review and adoption.
The Pharma Data
MAY 4, 2021
It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.
Expert insights. Personalized for you.
52 
Let's personalize your content